OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to provide shareholders additional insight as to the Company's ongoing initiative to acquire Mexican Joint Venture partner Vitel Laboratorios, S.A. de C.V. ("Vitel"). In September, OncBioMune disclosed negotiating a potential merger, which resulted in the signing of a non-binding term sheet, as disclosed on November 3, 2016. The legal teams for each company are actively working on definitive agreement documents to create a binding arrangement, which would entail Vitel becoming a wholly owned subsidiary of OncBioMune.
Currently, OncBioMune and Vitel have agreed in principle that the acquisition will transfer rights to Vitel's portfolio of products to OncBioMune, as well as establish new relationship between OncBioMune and Vitel's current network of distribution, proprietary rights, Joint Venture and licensing partners.
Vitel presently has Mexican territorial rights through licensing agreements with Roha Arnzemittel, GmbH ("Roha") for Bekunis® (for constipation) and Cirkused® (for stress), as well as licensing rights to the remainder of Roha's pipeline at Vitel's discretion. These products were commercialized in September by Vitel and have generated approximately $100,000USD in revenue in approximately six weeks of an initial re-launch to the Mexican markets.
Vitel also has Mexican territorial rights through licensing agreements with Cheplapharm Arzneimittel GmbH for Vesanoid® (for cancer); Kamada for KamRab® (for rabies), KamRho® (an Rh immunization) and Glassia® (for Anti-D deficiency); Aqvida for Imatinib (for cancer), Docetaxel (for cancer), Azathriopine (an immunosuppressive drug); and QPharma for Androferti (a male fertility drug).
For Mexico, Central and Latin America, Vitel has Joint Venture partnerships forged for development and commercialization of several products, including, Gem Pharmaceuticals for GPX-150 (for sarcoma); EOC Pharma for Telatinib (for first line gastric cancer treatment); and Rational Vaccines for the first and only herpes Vaccine technology for the treatment of HSV-2 and HSV-1.
Further, Vitel is under development of world right agreements with confidential partners for the moment, where R&D and unique innovation is involved.
In addition to the product pipeline and partners, Vitel's network channel partners cover the gamut of drug development and marketing. A sampling of relationships includes, CID Information Systems (marketing intelligence), Grupo Nichos (pharmaceutical salesforce, demand generation), CeroGrados (pharmaceutical warehousing, and old chain), CRO's authorized by the COFEPRIS and Regulatory Affairs parties that are authorized by the COFEPRIS for dossier build up and pre-inspection.
"I think it is pretty clear why we are excited to be working with Vitel on ProscaVax for development south of the U.S. border and why the acquisition of Vitel brings tremendous value to OncBioMune from the outset," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "The long standing relationships they have with some of the venerable companies in the pharmaceutical space in Mexico and throughout Latin America is something that takes years to develop. Upon completing the acquisition we immediately become a respected player in the space, which will be invaluable with moving forward with our aggressive growth plans."
While the acquisition is moving forward in good faith, interested parties are advised that the acquisition of Vitel by OncBioMune remains subject to the execution of a definitive agreement containing customary representations, warranties, and closing conditions, completion of due diligence and approval by the respective boards of directors of OncBioMune and Vitel.
Recent THER News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:29:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 08:35:09 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 02/15/2024 10:28:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/15/2024 08:00:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 01:10:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 11:28:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 11:17:03 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 12/29/2023 04:26:15 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 09:51:04 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM